Phase 3 Endometriosis Trial, Recruiting NCT07164183 Sponsor: Alcea Condition: Endometriosis
Back to Endometriosis

Phase 3 Endometriosis Trial, Recruiting

NCT07164183
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are willing and able to sign a written consent form to take part in the study
  • You are a woman of childbearing age (premenopausal) between 18 and 45 years old
  • You have been diagnosed with endometriosis (stage I, II, or III) through surgery (laparoscopy or laparotomy) at least 2 weeks ago but no more than 60 months (5 years) ago
  • Your periods happen naturally (without hormonal treatment) and come every 24 to 38 days, and this has been the case for the past 2 cycles and during the screening period
  • You do not currently need surgery for your endometriosis
  • You have had pelvic pain related to endometriosis that scores 3.5 or higher on a 10-point pain scale, both in the 2 cycles before screening and during the screening cycle
  • You have other symptoms of endometriosis, such as painful periods, pain during sex, pain when going to the toilet, or findings shown on an ultrasound or MRI scan
  • You agree to use highly effective contraception throughout the study and for 2 months after it ends
  • You have a negative pregnancy test
  • You filled in a daily symptom diary on at least 75% of days during the screening period

Who may not be able to join:

  • You have a known reason why you cannot take the study drug Indinol Forto (indolcarbinol)
  • You have a known reason why you cannot take the study drug Visanne (dienogest)
  • You have had unexplained or abnormal vaginal or urinary bleeding in the past 6 months
  • You have long-term pelvic pain caused by something other than endometriosis, such as fibroids or another gynaecological or urological condition
  • You have long-term pain in other parts of the body not caused by endometriosis (for example, fibromyalgia, ongoing back pain, or frequent headaches) that requires ongoing pain treatment
  • You have endometrioid cysts that are 3 cm or larger
  • You have had your uterus removed (hysterectomy), both ovaries removed (bilateral oophorectomy), or have premature ovarian failure (note: having had your tubes tied or removed is allowed)
  • You have another significant gynaecological condition found during screening, such as ovarian cysts larger than 3 cm lasting more than 4 months, or an active sexually transmitted infection (confirm with trial site — rescreening may be possible after treatment)
  • Your endometriosis pain has not improved at all with previous treatments such as the contraceptive pill, hormone therapies, or similar medications (note: partial response or stopping due to side effects may still be acceptable — confirm with trial site)
  • You have had cancer in the past 5 years, except for certain treated skin cancers or cervical cancer in situ
  • You have severe kidney disease (confirm with trial site)
  • Your blood pressure is too high during the screening period (above 160/90 mmHg)
  • Your blood test results during screening show significant problems with liver function, low red blood cells (anaemia), or low white blood cells or platelets
  • You have an overactive or underactive thyroid gland based on blood test results
  • You are pregnant, have been pregnant in the last 3 months, or are currently breastfeeding
  • You have a history of alcohol or drug misuse
  • You have taken part in another clinical trial within the past 90 days
  • You have any other medical condition, need for surgery, or required treatment that the study doctor believes could make participation unsafe or affect the study results

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Alcea
Registry
ClinicalTrials.gov
Start date
11 September 2025
Est. completion
1 October 2026

Where this trial is recruiting

🇷🇺 Russia

Primary endpoints

Average daily pelvic pain score, combined

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov